Regulation of tumor immunity by tumor/dendritic cell fusions.

Abstract

The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.

• Authors: Shigeo Koido, Sadamu Homma, Eiichi Hara, Yoshihisa Namiki, Akitaka Takahara, Hideo Komita, Eijiro Nagasaki, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
• Journal: Clinical & developmental immunology (Clin Dev Immunol) Vol. 2010 Pg. 516768 ( 2010) ISSN: 1740-2530 [Electronic] Egypt
• PMID: 21048993 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antigens, Neoplasm
• Cancer Vaccines

Topics

• Animals
• Antigens, Neoplasm (immunology)
• Cancer Vaccines
• Cell Fusion (methods)
• Clinical Trials as Topic
• Dendritic Cells (immunology)
• Humans
• Lymphocyte Activation
• Neoplasms (immunology, pathology, therapy)
• T-Lymphocytes, Cytotoxic (immunology)
• Tumor Escape (immunology)
• Tumor Microenvironment (immunology)